- Trials with a EudraCT protocol (124)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
124 result(s) found for: Liquid biopsy.
Displaying page 1 of 7.
EudraCT Number: 2019-002074-32 | Sponsor Protocol Number: IFOM-CPT005/2019/PO004 | Start Date*: 2020-02-11 | |||||||||||
Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare | |||||||||||||
Full Title: POST-SURGICAL LIQUID BIOPSY-GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS | |||||||||||||
Medical condition: Stage III and high-risk stage II colon cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000575-88 | Sponsor Protocol Number: SHP647-305 | Start Date*: 2019-02-28 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305) | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000576-29 | Sponsor Protocol Number: SHP647-306 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306) | |||||||||||||
Medical condition: Crohn’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) HU (Completed) SK (Completed) ES (Prematurely Ended) PT (Completed) EE (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001328-17 | Sponsor Protocol Number: IMIB-HTF-2021-01 | Start Date*: 2021-09-23 |
Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia | ||
Full Title: Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. | ||
Medical condition: Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004519-38 | Sponsor Protocol Number: GEMCAD-17-01 | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD | |||||||||||||
Full Title: Randomized phase II study to evaluate the efficacy of second-line FOLFIRI + panitumumab in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line | |||||||||||||
Medical condition: Subjects treated in first-line with panitumumab and FOLFOX and having at least achieved stable disease with wild type RAS metastatic Colorectal Cancer confirmed in liquid biopsies before starting s... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004259-38 | Sponsor Protocol Number: CAC-91-10-10 | Start Date*: 2011-10-06 | |||||||||||
Sponsor Name:Asklepion Pharmaceuticals, LLC | |||||||||||||
Full Title: Investigation in the Pathogenesis of Liver Disease in Patients with Inborn Errors of bile Acid Metabolism | |||||||||||||
Medical condition: Patients with inborn errors of bile acid synthesis and metabolism | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001066-15 | Sponsor Protocol Number: LR19912019 | Start Date*: 2019-08-16 | |||||||||||
Sponsor Name:Merete Hædersdal | |||||||||||||
Full Title: Treatment of hypertrophic scars using needle-free jet-injection of triamcinolone and 5-Fluorouracile: a prospective, controlled, randomized, single-blinded split-lesion trial. | |||||||||||||
Medical condition: Hypertrophic scars on 20 participants | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000248-23 | Sponsor Protocol Number: C3441052 | Start Date*: 2021-10-22 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | |||||||||||||
Medical condition: Metastatic Castration-sensitive Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003787-21 | Sponsor Protocol Number: FIRE-4 | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:Klinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion) | |||||||||||||
Full Title: Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab | |||||||||||||
Medical condition: Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily non-resectable or with surgery refused by the patient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002369-36 | Sponsor Protocol Number: GECP19/01 | Start Date*: 2020-04-18 | |||||||||||
Sponsor Name:Fundación GECP | |||||||||||||
Full Title: Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study | |||||||||||||
Medical condition: ALK+ non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001335-12 | Sponsor Protocol Number: D5160C00030 | Start Date*: 2016-05-12 |
Sponsor Name:Hellenic Oncology Research Group | ||
Full Title: A longitudinal study evaluating molecular changes associated with resistance to first and third (AZD9291) generation EGFR TKIs in patients with EGFR mutant NSCLC using "liquid biopsy" | ||
Medical condition: Patients with NSCLC | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003732-20 | Sponsor Protocol Number: GECP16/03 | Start Date*: 2017-01-24 |
Sponsor Name:Grupo Español de Cáncer de Pulmón | ||
Full Title: NEO -ADJUVANT CHEMO/IMMUNOTHERAPY FOR THE TREATMENT OF RESECTABLE STAGE IIIA NON SMALL CELL LUNG CANCER (NSCLC): A PHASE II MULTICENTER EXPLORATORY STUD | ||
Medical condition: Non small cell lung cáncer limited stage IIIA | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2021-000689-14 | Sponsor Protocol Number: FINPROVE | Start Date*: 2021-10-06 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile | ||
Medical condition: Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as reveale... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005078-82 | Sponsor Protocol Number: LIBImAB | Start Date*: 2021-03-23 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA | ||||||||||||||||||
Full Title: Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuximAb or BevacizumAb | ||||||||||||||||||
Medical condition: Patients with metastatic colorectal cancer RAS/BRAF wild type not previously treated in metastatic setting | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003573-26 | Sponsor Protocol Number: TRAMAV02092019 | Start Date*: Information not available in EudraCT |
Sponsor Name:Cliniques universitaires Saint-Luc | ||
Full Title: Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated | ||
Medical condition: Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004414-35 | Sponsor Protocol Number: IMPRESSNorway | Start Date*: 2021-02-19 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Improving public cancer care by implementing precision medicine in Norway | ||
Medical condition: Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002285-23 | Sponsor Protocol Number: POETIG | Start Date*: 2017-01-18 | |||||||||||
Sponsor Name:Universitaetsklinikum Essen | |||||||||||||
Full Title: Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POna... | |||||||||||||
Medical condition: gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004299-41 | Sponsor Protocol Number: ERMES | Start Date*: 2014-12-24 | |||||||||||
Sponsor Name:Dipartimento di Scienze Mediche Oncologia Medica Policlinico Gemelli | |||||||||||||
Full Title: ERbitux MEtastatic colorectal cancer Strategy Study: A phase III randomized two arm study with FOLFIRI + Cetuximab until disease progression compared to FOLFIRI + Cetuximab for 8 cycles followed by... | |||||||||||||
Medical condition: Patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005437-32 | Sponsor Protocol Number: ERASE-TMZ | Start Date*: 2021-03-10 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva... | ||||||||||||||||||
Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001172-11 | Sponsor Protocol Number: MedOPP239 | Start Date*: 2020-03-10 | |||||||||||
Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||
Full Title: A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy ... | |||||||||||||
Medical condition: Unresectable locally advanced or metastatic penile squamous cell carcinoma (PSqCC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
